Benztropine
Cogentin (benztropine) is a small molecule pharmaceutical. Benztropine was first approved as Cogentin on 1982-01-01. It is used to treat drug-induced abnormalities and parkinson disease in the USA. It is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M1, sodium-dependent dopamine transporter, and sodium-dependent neutral amino acid transporter B(0)AT1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
benztropine mesylate | ANDA | 2023-06-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
drug-induced abnormalities | — | D000014 | — |
parkinson disease | EFO_0002508 | D010300 | G20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
J0515 | Injection, benztropine mesylate, per 1 mg |
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | BENZTROPINE |
INN | benzatropine |
Description | Benzatropine is tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments. It has a role as an antiparkinson drug, a parasympatholytic, an antidyskinesia agent, a muscarinic antagonist and a oneirogen. |
Classification | Small molecule |
Drug class | atropine derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1[C@H]2CC[C@@H]1C[C@H](OC(c1ccccc1)c1ccccc1)C2 |
Identifiers
PDB | — |
CAS-ID | 86-13-5 |
RxCUI | — |
ChEMBL ID | CHEMBL1201203 |
ChEBI ID | 3048 |
PubChem CID | 1201549 |
DrugBank | DB00245 |
UNII ID | 1NHL2J4X8K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CHRM2
CHRM2
CHRM1
CHRM1
SLC6A3
SLC6A3
SLC6A19
SLC6A19
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,533 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more